It is used for the treatment of hepatitis Cvirus (HCV) infection.
Compared to previous treatments, Cimivir (Sofosbuvir )-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy.
Cimivir (Sofosbuvir ) allows most patients to be treated successfully without the use of peginterferon,an injectable drug with severe side effects.
that is a key component of older drug combinations for the treatment of HCV.Cimivir (Sofosbuvir ) is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3, and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone.
It is also used in combination with the viral NS5a inhibitor ledipasvir in an interferon-free combination for the treatment of genotype 1 hepatitis C infection.
Cimivir (Sofosbuvir ) is also used in HCV patients with an HIV coinfection.
The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of Cimivir (Sofosbuvir ) plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.
Mechanism of action:
Cimivir (Sofosbuvir ) contains oral nucleotide analog inhibitor of the hepatitis C virus (HCV) polymerase.
The drug is a direct-acting antiviral agent and interferes straight with the HCV lifecycle, restraining the viral replication.
It can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator. The drug is available for oral use in the form of 400mg tablets.
Dosage and Administration:
The recommended daily dose of Cimivir (Sofosbuvir ) is 400mg tablet to be taken once daily with or without food. Cimivir (Sofosbuvir ) should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC (Chronic Hepatitis C) in adults.
It is highly advisable to administer the drug under strict medical supervision and advice.
Adverse events associated with the use of Cimivir (Sofosbuvir ) in combination with Ribavirin may include, but are not limited to, the followingo Fatigue , headacheAdverse events associated with the use of Cimivir (Sofosbuvir ) in combination with Peginterferon Alfa and Ribavirin may include, but are not limited to, the following:o fatigue,headache, nausea, insomnia, anemia